Profermin®: Prevention of Progression in Alcoholic Liver Disease by

Status Active, not recruiting

Clinical Trial Summary

Investigators wishes to influence the gut microbiota in patients with alcoholic liver disease in a randomized controlled clinical trial. The investigators hypothesize that the alcohol-related dysbiosis seen in these patients can be changed and disease progression haltered by modulating microbiota with probiotics during 24 weeks.

Clinical Trial Description

Chronic alcohol overuse is associated with increased gut permeability and in addition, the intestinal microbiota changes qualitatively (dysbiosis) and quantitatively (bacterial overgrowth) in alcoholic liver disease in favour of a microbiota with increased invasive potential. As a consequence, an increased load of bacterial products is transported to the liver leading to inflammation and fibrogenesis. This cross talk between the intestinal microbiota and the liver constitute a gut-liver axis, which is increasingly recognized as key mechanism in the progression of liver disease and pathogenesis of liver related complications. The investigators hypothesize that the gut microbiota and its metabolites are major drivers of fibrosis in human liver disease and that modulating the intestinal flora by Profermin® (a food for special medical purposes) will modulate the alcohol related dysbiotic signatures in the microbiota which may halter disease progression by reducing activity of hepatic stellate cells. Dietary supplements that alter the microbiome towards a more beneficent type may improve liver inflammation and thus be a better alternative than supplements that simply add nutrients. Investigators expect that the trial will provide proof-of-concept for a sustainable dietary strategy in liver fibrosis. Examples of biopsies which did not meet quality criteria for reliable histological reading, led to inclusion of 16 extra patients. In total we included 56 patients to ensure an adequate number of participants with valid liver biopsy data for assessment of the primary endpoint and intention-to-treat analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03863730
Study type	Interventional
Source	Odense University Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 1, 2019
Completion date	February 2031

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Recruiting	`NCT06051669` - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Completed	`NCT06244550` - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	N/A
Recruiting	`NCT06098417` - Biomarkers in the Diagnosis and Prognosis of NAFLD
Not yet recruiting	`NCT03623360` - Functional MRI to Determine Severity of Cirrhosis
Recruiting	`NCT01965418` - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial	Phase 4
Not yet recruiting	`NCT01133184` - Improved Prevention of Perinatal Hepatitis B Transmission	Phase 4
Completed	`NCT00043303` - Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis	Phase 2
Completed	`NCT03872024` - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients	N/A
Recruiting	`NCT05912179` - Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
Recruiting	`NCT04533828` - 68Ga-FAPI PET/CT in Liver Fibrosis Patients	Early Phase 1
Completed	`NCT04573543` - The Role of Immune Semaphorins in NAFLD
Recruiting	`NCT03277651` - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension	N/A
Completed	`NCT01707472` - Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis	Phase 2
Not yet recruiting	`NCT05935488` - Early Liver Disease Breath Detection
Completed	`NCT02060162` - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3
Completed	`NCT01810458` - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Completed	`NCT01988753` - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed	`NCT00049842` - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota — SYN-ALD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms